Microbot Medical Inc. (MBOT) announced that it has completed its limited market release of the LIBERTY Endovascular Robotic System and will begin a full market release in the United States at the Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto, Canada, from April 11‑15, 2026.
The LIBERTY system received FDA 510(k) clearance on September 8, 2025, and is the first FDA‑cleared, single‑use, remotely operated robotic platform for endovascular interventions. The product has already been adopted by Emory Healthcare and Tampa General Hospital, and the full market launch will expand availability to additional hospitals across the country.
Microbot plans to broaden its sales footprint from four to eight territories with the full market release, targeting coverage of 12 territories by the end of 2026. The company’s strategy is to accelerate commercial adoption, generate the first revenue streams, and validate a disposable model that could unlock a $2.5 billion U.S. market for peripheral interventions.
Financially, Microbot remains unprofitable. In Q1 2025 the company reported a net loss of $2.6 million, compared with $2.37 million a year earlier. In Q4 2025 the company posted an EPS of –$0.04 versus an analyst expectation of –$0.06, a beat of $0.02. The next earnings report is expected around May 13, 2026.
The announcement was well received by investors, with analysts noting the significance of the full market release and the company’s progress toward commercializing its flagship product.
"We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference," said Harel Gadot, Chairman, President and CEO. "Obtaining FDA 510(k) clearance for LIBERTY marks a defining moment for Microbot Medical and, we believe, for the future of endovascular robotics. This achievement validates our mission to expand access to advanced robotic technologies while addressing critical unmet needs and supporting cost‑effective healthcare," he added. "With our commercial readiness strategy being developed and executed since Q2 this year, we believe we are well positioned to accelerate market entry."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.